Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

December 20 2022Regulatory
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023

December 19 2022Regulatory
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized

November 9 2022Regulatory
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)

November 2 2022Regulatory
Verona Pharma Announces November 2022 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following conferences in November 2022: Stifel 2022 Healthcare Conference Date: Tuesday, November 15, 2022 Time:

October 26 2022Regulatory
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30,

October 17 2022Regulatory
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

Non-dilutive capital finances planned launch of ensifentrine for COPD LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with with access to up to $150 million from Oxford Finance LLC (“Oxford”).

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2023. All rights reserved